Your browser doesn't support javascript.
loading
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein, R; Sotlar, K; Gluz, O; Otremba, B; von Schumann, R; Witzel, I; Schindlbeck, C; Janni, W; Schem, C; Bauerfeind, I; Hasmueller, S; Tesch, H; Paulenz, A; Ghali, N; Orujov, E; Kates, R E; Cowens, W; Hornberger, J; Pelz, E; Harbeck, N.
Afiliação
  • Wuerstlein R; a West German Study Group , Moenchengladbach , Germany ;
  • Sotlar K; b Breast Center, University of Munich (LMU) and CCCLMU , Munich , Germany ;
  • Gluz O; c University Clinics Munich (LMU), Institute of Pathology , Munich , Germany ;
  • Otremba B; a West German Study Group , Moenchengladbach , Germany ;
  • von Schumann R; d Ev. Hospital Bethesda - Breast Center Niederrhein , Moenchengladbach , Germany ;
  • Witzel I; e Oncologic Practice Oldenburg/Delmenhorst , Oldenburg , Germany ;
  • Schindlbeck C; a West German Study Group , Moenchengladbach , Germany ;
  • Janni W; d Ev. Hospital Bethesda - Breast Center Niederrhein , Moenchengladbach , Germany ;
  • Schem C; f University Clinics Hamburg-Eppendorf , Hamburg , Germany ;
  • Bauerfeind I; g Clinics Traunstein , Traunstein , Germany ;
  • Hasmueller S; h University Clinics Ulm , Ulm , Germany ;
  • Tesch H; i University Clinics Kiel , Kiel , Germany ;
  • Paulenz A; j Clinics Landshut , Department of Obstetrics and Gynecology & Interdisciplinary Breast Cancer Center , Landshut , Germany ;
  • Ghali N; k Kreisklinik Ebersberg , Ebersberg , Germany ;
  • Orujov E; l Oncological Practice Bethanien , Frankfurt , Germany ;
  • Kates RE; m Clinics Ernst von Bergmann , Potsdam , Germany ;
  • Cowens W; n NanoString Technologies Inc. , Seattle , WA , USA ;
  • Hornberger J; n NanoString Technologies Inc. , Seattle , WA , USA ;
  • Pelz E; a West German Study Group , Moenchengladbach , Germany ;
  • Harbeck N; n NanoString Technologies Inc. , Seattle , WA , USA ;
Curr Med Res Opin ; 32(7): 1217-24, 2016 07.
Article em En | MEDLINE | ID: mdl-26971372
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Quimioterapia Adjuvante / Receptor ErbB-2 / Antineoplásicos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Curr Med Res Opin Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Quimioterapia Adjuvante / Receptor ErbB-2 / Antineoplásicos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Curr Med Res Opin Ano de publicação: 2016 Tipo de documento: Article